In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan Recovery Slowed By King

Executive Summary

King Pharmaceuticals' decision to abandon its $850 million purchase of Elan's primary care franchise is the first serious setback to the embattled Irish firm's recovery plan. But with several remaining saleable assets and a potential blockbuster in Phase III autoimmune therapy Antegren, all is not lost.
Advertisement

Related Content

Antegren: Shaking Up the MS Market?
Can an Overthrown King Help Mylan?
Medeus: How To Find & Buy a Ready-Made Euro Infrastructure
Strakan: Refining Search & Development
Crohn's Disease: European Contenders Lead
Delivering Profits at SkyePharma
Sepracor's Primary Care Ambitions
CeNeS' Last Shot?
Biogen Defends its Specialist Market
The FASB Nightmare

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel